Stock SRZN SURROZEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Surrozen, Inc.

Equities

SRZN

US86889P2083

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
10.95 USD +10.16% Intraday chart for Surrozen, Inc. +13.00% +16.49%
06-10 Surrozen, Inc. Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver in Milan CI
06-04 Surrozen Begins Dosing First Patient in Phase 1 Trial for Alcohol-Related Hepatitis Treatment MT

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 225.6 17.31 19.16 35.03 -
Enterprise Value (EV) 1 123.7 -58.53 -16.88 16.43 -49.17
P/E ratio -2.91 x -0.56 x -0.44 x -0.92 x -1.88 x
Yield - - - - -
Capitalization / Revenue - 1.38 x - - -
EV / Revenue - -4.68 x - - -
EV / EBITDA -2,364,557 x 1,380,995 x - - -
EV / FCF - 1,304,394 x - - -
FCF Yield - 0% - - -
Price to Book - 0.27 x - - -
Nbr of stocks (in thousands) 2,335 1,983 2,038 3,199 -
Reference price 2 96.60 8.728 9.400 10.95 10.95
Announcement Date 3/24/22 3/22/23 4/10/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 - - 12.5 - - -
EBITDA - -52.32 -42.38 - - -
EBIT 1 - -54.39 -44.34 -45.78 -36.5 -38.3
Operating Margin - - -354.71% - - -
Earnings before Tax (EBT) - -54.65 -36 -43.04 - -
Net income 1 -32.72 -54.65 -36 -43.04 -36.2 -38.3
Net margin - - -288.03% - - -
EPS 2 -66.30 -33.15 -15.60 -21.33 -11.87 -5.830
Free Cash Flow - - -44.87 - - -
FCF margin - - -358.98% - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 5/14/21 3/24/22 3/22/23 4/10/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - 12.5 - - - - - - - -
EBITDA - - - - - - - - - - - - -
EBIT 1 -15 -14.49 -14.07 -13.6 -2.169 -14.59 -10.28 -11.19 -9.724 -9.13 -9.1 -9.1 -9.1
Operating Margin - - - - -17.35% - - - - - - - -
Earnings before Tax (EBT) -14.95 -7.947 -13.92 -13.36 -0.775 -14.3 -9.387 -10.44 -8.913 -8.83 - - -
Net income 1 -14.95 -7.947 -13.92 -13.36 -0.775 -14.3 -9.387 -10.44 -8.913 -8.83 -9.1 -9.1 -9.1
Net margin - - - - -6.2% - - - - - - - -
EPS 2 -5.250 -3.450 -6.000 -5.700 -0.4500 -7.200 -4.650 -5.100 -4.380 -4.240 -2.790 -2.710 -2.630
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/24/22 5/11/22 8/11/22 11/14/22 3/22/23 5/10/23 8/9/23 11/8/23 4/10/24 5/8/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - -
Net Cash position 1 - 102 75.8 36 18.6 84.2
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - -44.9 - - -
ROE (net income / shareholders' equity) - -69.6% -38.8% - - -
ROA (Net income/ Total Assets) - - -31.8% - - -
Assets 1 - - 113.3 - - -
Book Value Per Share - - 32.80 - - -
Cash Flow per Share - -29.70 -19.10 - - -
Capex 1 - 1.27 0.73 0.4 1.4 1.4
Capex / Sales - - 5.82% - - -
Announcement Date 5/14/21 3/24/22 3/22/23 4/10/24 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
10.95 USD
Average target price
33 USD
Spread / Average Target
+201.37%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SURROZEN, INC. Stock Surrozen, Inc.
+16.49% 35.03M
MODERNA, INC. Stock Moderna, Inc.
+19.41% 45.51B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.62% 38.52B
LONZA GROUP AG Stock Lonza Group AG
+38.51% 38.13B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+26.95% 30.74B
CELLTRION, INC. Stock Celltrion, Inc.
-13.50% 26.03B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.74% 25.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.87% 14.13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+34.36% 12.73B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.14% 11.29B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SRZN Stock
  4. Financials Surrozen, Inc.